Pepper-Based patch may ease chronic pelvic pain by resetting nerve sensitivity

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women ≥ 18 years old. * Patients suffering from chronic pelvi-perineal neuralgia (\>3 months) with a DN4 score ≥4 at the inclusion visit, with or without symptoms of central sensitization, and with an indication for topical treatment with high-concentration capsaicin patch (PCHC). * Patients who have signed the informed consent form for the study at the inclusion visit. * Women must meet one of the following criteria at the time of inclusion: * Use adequate contraceptive measures; * or Be postmenopausal (aged over 50 years with amenorrhea for at least 12 months after discontinuation of all exogenous hormonal treatments); * or (If aged under 50 years) have been amenorrheic for at least 12 months after discontinuation of exogenous hormonal treatments, with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels consistent with postmenopausal levels; * or Have undergone irreversible surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), with documentation of the procedure. Exclusion Criteria: * Patients under guardianship, curatorship, or legal protection. * Pregnant or breastfeeding women. * Patients with contraindications to the use of the high-concentration capsaicin patch (PCHC): application on damaged skin, hypersensitivity to any of its components. * Patients simultaneously starting a treatment that may influence central sensitization (e.g., antidepressants, antiepileptics, psychotherapy, physical activity, transcutaneous electrical nerve stimulation). * Patients not affiliated with the French Social Security system. * Patients with insufficient cooperation and/or understanding to strictly comply with the protocol requirements. * Patients who have taken analgesics within the 12 hours prior to measurements.